Ranpirnase Active in Mesothelioma, Might Improve Survival in Some
No overall survival advantage was observed with ranpirnase compared with doxorubicin in unresectable malignant mesothelioma, though a trend toward benefit was seen in good-prognosis patients.
A phase III study comparing ranpirnase with doxorubicin in unresectable malignant mesothelioma found no overall survival advantage, but a trend toward benefit in patients with good prognosis.
Mesothelioma lacks standard effective therapies; determining whether ranpirnase offers a survival benefit informs clinical decision‑making and guides future trial design.
Evidence level: Állatkísérletes. Állatmodellben vizsgálták.
Related signals
- The dual axis of tumorigenesis: MAPK and PI3K/AKT pathways in papillary thyroid carcinoma
- The molecular mechanisms and potential therapeutic implications of the crosstalk between DNA methylation and metabolic reprogramming in thyroid cancer
- Improving predicted risk of recurrence using molecular profiling in papillary thyroid cancer
- Global Burden of Thyroid Cancer in Adults Age 15‑49 Years and Its Predictions: Findings From Global Burden of Disease Study 2021
- Thyroid Cancer: Pathogenesis, Clinicopathology, Diagnosis, and Management